JNJ. P/E of 15-16 depending on time period.
Getting very close to 50% of sales from outside the US.
Within the US, about as recession-proof as it gets.
Their annual report came out recently - check out the subsegments of their three main segments, which are consumer, pharma, and medical devices. This is the P&G of healthcare.
Check out the R&D spending, and the 75 years of sales growth.
Check out the list of brands.
Check out ROEs and margins.
Check out use of debt, debt types (short-vs long-term) and coverage ratios.
If you can tell us why this company should not be priced like a growth company, why it should not have at least the same P/E as a commodity company (whose moats are not protected by trademarks, patents and research), we would appreciate hearing from you.
Subscribe to:
Post Comments (Atom)
1 comment:
JNJ gets >40% of profits from pharma and has pipeline issues like a lot of those companies. Their dividend yield is well below Pfizer's and their high market cap means that even a blockbuster drug will have a negligible impact on the value of their enterprise.
Troy
Post a Comment